Почетна › Рак дојке › Džordžija
Kliničke studije za Рак дојке u državi Džordžija
52 studija za Рак дојке traži učesnike na lokacijama u državi Džordžija.
Gradovi u državi Džordžija
- Atlanta42 студија
- Savannah12 студија
- South Fulton6 студија
- Athens5 студија
- Augusta5 студија
- Johns Creek4 студија
- Sandy Springs3 студија
Zvanični tekst studije (na engleskom)
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
- Grady Memorial Hospital, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07748208Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Emory University School of Medicine, Atlanta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Summit Cancer Care, Savannah
Тражи се учесникФаза 1
Узраст од 18 до 55 · Жене · Ажурирано 12. 11. 2026. · NCT07310420S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- Northeast Georgia Medical Center-Gainesville, Gainesville
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Atlanta
Тражи се учесникФаза 1/2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT06590857A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06827236A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Atlanta Cancer Care - Northside Hospital, Atlanta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- University Cancer & Blood Center, LLC, Athens
- Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
- Central Georgia Cancer Care, Macon
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Northwest Georgia Oncology Centers PC - Marietta, Marietta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- и још 4
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Winship Cancer Institute, Atlanta
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- и још 4
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Northside Hospital, Atlanta
- John B Amos Cancer Center, Columbus
- Northside Hospital - Duluth, Duluth
- и још 5
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07114601Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phoebe Putney Memorial Hospital, Albany
- University Cancer and Blood Center LLC, Athens
- Grady Health System, Atlanta
- и још 17
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Emory University Winship Cancer Institute, Atlanta
- Liberty County Cancer Care, Hinesville
- Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
- и још 2
Тражи се учесникФаза 3
Узраст 60 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06377852Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07288359A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Emory University Hospital, Atlanta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT05646862A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Marietta
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 19. 10. 2026. · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital, Atlanta
- Investigational Drug Service Emory University Clinic, Atlanta
- и још 4
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Winship Cancer Institute, Emory University, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06369285Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Emory Proton Therapy Center, Atlanta
Тражи се учесникФаза 3
Узраст 19 и старији · Жене · Ажурирано 29. 9. 2026. · NCT05856773Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Marietta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07085767A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT05570253Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT05846789Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06072612A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Augusta University, Augusta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 21. 8. 2026. · NCT06764940Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
- Emory University Hospital/Winship Cancer Institute, Atlanta
Тражи се учесникЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT07764796FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 8. 2026. · NCT05304962Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Winship Cancer Institute at Emory University, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 8. 2026. · NCT06263543A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Atlanta, Newnan
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 6. 8. 2026. · NCT05232916First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.